Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Aug;30(2):287–291. doi: 10.1111/j.1365-2125.1990.tb03777.x

In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme.

N A Helsby 1, S A Ward 1, R E Howells 1, A M Breckenridge 1
PMCID: PMC1368230  PMID: 2206791

Abstract

The metabolic activation of the arylbiguanide antimalarials proguanil (PG) and chlorproguanil (CPG) has been investigated in liver microsomes from three human livers. All three microsomal preparations activated the biguanides. The kinetic parameters for PG metabolism to cycloguanil (CG) were Km 21.8, 29.6 and 26.4 microM and Vmax 1.5, 5.9, and 8.2 pmol min-1 mg-1. The values for CPG conversion to chlorcycloguanil (CCG) were Km 12.9, 19.7 and 26.1 microM and Vmax 5.7, 4.8 and 3.6 pmol min-1 mg-1. The metabolic activation of both biguanides was competitively inhibited by the anticonvulsant mephenytoin. Sparteine and tolbutamide had no effect on biguanide metabolism. These data suggest an involvement of the mephenytoin hydroxylase enzyme, which exhibits a genetic polymorphism in man, in the metabolic activation of the biguanide antimalarials.

Full text

PDF
287

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alvares A. P., Anderson K. E., Conney A. H., Kappas A. Interactions between nutritional factors and drug biotransformations in man. Proc Natl Acad Sci U S A. 1976 Jul;73(7):2501–2504. doi: 10.1073/pnas.73.7.2501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Boobis A. R., Murray S., Kahn G. C., Robertz G. M., Davies D. S. Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man. Mol Pharmacol. 1983 Mar;23(2):474–481. [PubMed] [Google Scholar]
  3. CARRINGTON H. C., CROWTHER A. F., DAVEY D. G., LEVI A. A., ROSE F. L. A metabolite of paludrine with high antimalarial activity. Nature. 1951 Dec 22;168(4288):1080–1080. doi: 10.1038/1681080a0. [DOI] [PubMed] [Google Scholar]
  4. DIXON M. The determination of enzyme inhibitor constants. Biochem J. 1953 Aug;55(1):170–171. doi: 10.1042/bj0550170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dollery C. T., Fraser H. S., Mucklow J. C., Bulpitt C. J. Contribution of environmental factors to variability in human drug metabolism. Drug Metab Rev. 1979;9(2):207–220. doi: 10.3109/03602537908993891. [DOI] [PubMed] [Google Scholar]
  6. Eichelbaum M., Spannbrucker N., Steincke B., Dengler H. J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979 Sep;16(3):183–187. doi: 10.1007/BF00562059. [DOI] [PubMed] [Google Scholar]
  7. Jacqz E., Hall S. D., Branch R. A., Wilkinson G. R. Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital. Clin Pharmacol Ther. 1986 Jun;39(6):646–653. doi: 10.1038/clpt.1986.113. [DOI] [PubMed] [Google Scholar]
  8. Kahn G. C., Boobis A. R., Brodie M. J., Toverud E. L., Murray S., Davies D. S. Phenacetin O-deethylase: an activity of a cytochrome P-450 showing genetic linkage with that catalysing the 4-hydroxylation of debrisoquine? Br J Clin Pharmacol. 1985 Jul;20(1):67–76. doi: 10.1111/j.1365-2125.1985.tb02800.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kelly J. A., Fletcher K. A. High-performance liquid chromatographic method for the determination of proguanil and cycloguanil in biological fluids. J Chromatogr. 1986 Sep 5;381(2):464–471. doi: 10.1016/s0378-4347(00)83616-6. [DOI] [PubMed] [Google Scholar]
  10. Küpfer A., Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol. 1984;26(6):753–759. doi: 10.1007/BF00541938. [DOI] [PubMed] [Google Scholar]
  11. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  12. Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of Debrisoquine in man. Lancet. 1977 Sep 17;2(8038):584–586. doi: 10.1016/s0140-6736(77)91430-1. [DOI] [PubMed] [Google Scholar]
  13. Meier U. T., Dayer P., Malè P. J., Kronbach T., Meyer U. A. Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo. Clin Pharmacol Ther. 1985 Nov;38(5):488–494. doi: 10.1038/clpt.1985.213. [DOI] [PubMed] [Google Scholar]
  14. Meier U. T., Meyer U. A. Genetic polymorphism of human cytochrome P-450 (S)-mephenytoin 4-hydroxylase. Studies with human autoantibodies suggest a functionally altered cytochrome P-450 isozyme as cause of the genetic deficiency. Biochemistry. 1987 Dec 15;26(25):8466–8474. doi: 10.1021/bi00399a065. [DOI] [PubMed] [Google Scholar]
  15. Nakamura K., Goto F., Ray W. A., McAllister C. B., Jacqz E., Wilkinson G. R., Branch R. A. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther. 1985 Oct;38(4):402–408. doi: 10.1038/clpt.1985.194. [DOI] [PubMed] [Google Scholar]
  16. OMURA T., SATO R. THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. J Biol Chem. 1964 Jul;239:2370–2378. [PubMed] [Google Scholar]
  17. Oates N. S., Shah R. R., Idle J. R., Smith R. L. Phenformin-induced lacticacidosis associated with impaired debrisoquine hydroxylation. Lancet. 1981 Apr 11;1(8224):837–838. doi: 10.1016/s0140-6736(81)92711-2. [DOI] [PubMed] [Google Scholar]
  18. Purba H. S., Maggs J. L., Orme M. L., Back D. J., Park B. K. The metabolism of 17 alpha-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites. Br J Clin Pharmacol. 1987 Apr;23(4):447–453. doi: 10.1111/j.1365-2125.1987.tb03074.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Scott J., Poffenbarger P. L. Pharmacogenetics of tolbutamide metabolism in humans. Diabetes. 1979 Jan;28(1):41–51. [PubMed] [Google Scholar]
  20. Taylor R. B., Moody R. R., Ochekpe N. A. Determination of proguanil and its metabolites cycloguanil and 4-chlorophenylbiguanide in plasma, whole blood and urine by high-performance liquid chromatography. J Chromatogr. 1987 May 15;416(2):394–399. doi: 10.1016/0378-4347(87)80526-1. [DOI] [PubMed] [Google Scholar]
  21. Vesell E. S. Genetic and environmental factors affecting drug disposition in man. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 2):659–679. doi: 10.1002/cpt1977225part2659. [DOI] [PubMed] [Google Scholar]
  22. Ward S. A., Walle T., Walle U. K., Wilkinson G. R., Branch R. A. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther. 1989 Jan;45(1):72–79. doi: 10.1038/clpt.1989.11. [DOI] [PubMed] [Google Scholar]
  23. Ward S. A., Watkins W. M., Mberu E., Saunders J. E., Koech D. K., Gilles H. M., Howells R. E., Breckenridge A. M. Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. Br J Clin Pharmacol. 1989 Jun;27(6):781–787. doi: 10.1111/j.1365-2125.1989.tb03440.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Watkins W. M., Chulay J. D., Sixsmith D. G., Spencer H. C., Howells R. E. A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil. J Pharm Pharmacol. 1987 Apr;39(4):261–265. doi: 10.1111/j.2042-7158.1987.tb06263.x. [DOI] [PubMed] [Google Scholar]
  25. Wedlund P. J., Aslanian W. S., McAllister C. B., Wilkinson G. R., Branch R. A. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther. 1984 Dec;36(6):773–780. doi: 10.1038/clpt.1984.256. [DOI] [PubMed] [Google Scholar]
  26. Worsley D. E. Plasma Paludrine levels--some observations in Commonwealth troops in the Far East 1970. J R Army Med Corps. 1985 Oct;131(3):148–151. doi: 10.1136/jramc-131-03-07. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES